GVR Report cover Non-opioid Analgesics Market Size, Share & Trends Report

Non-opioid Analgesics Market Size, Share & Trends Analysis Report By Drug class (NSAIDs, Acetaminophen, Local Anesthetics), By Pain Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453176
  • Number of Pages: 0
  • Format: Electronic (PDF)

Non-opioid analgesics have broad applications in treating mild or severe pain, including pain associated with musculoskeletal, surgical, trauma, cancer, or other types of pain. In the last decade, the innovation in the market has been more likely limited to new extended-release formulations and new drug delivery systems. The advancements in delivery systems and new treatments offer improvements in symptom relief. However, effective analgesics with a low risk of intolerance and abuse are still a major unmet need in the market.

Rising restrictions on opioid-based products create lucrative opportunities for the non-opioid drug market. Opioid abuse and addiction, which includes prescription medications & drugs like fentanyl and heroin, is a critical global problem that negatively impacts public health and economic & social wellbeing. In the U.S., approximately 50,000 deaths occurred from opioid-related overdoses in 2021. In addition, according to data from Medicare, in the last decade, opioid prescriptions from oncologists declined by 21% and 23% from other doctors. Similarly, according to the report published by National Cancer Institute in 2021, the same trend had been observed among last-stage cancer patients. This trend is expected to continue during the forecast period, which has created a massive opportunity for space growth.

Analgesic drugs class has been mainly segmented as:

  • NSAIDs

  • Acetaminophen

  • Local Anesthetics

Investment in R&D has led to the development of novel therapeutic options that are highly effective, with lesser side effects. NSAIDs include a group of drugs used in pain, fever, and inflammation due to their analgesic, antipyretic, & anti-inflammatory properties. The space is strategically active with the approval of novel drugs. For instance, Heron Pharma’s ZYNRELEF, an extended-release dual-acting local anesthetic used as a single needle-free application, was approved by the U.S. FDA in May 2021. It is a unique drug for postoperative pain management associated with cancers and other surgeries. It is an essential milestone in ongoing efforts to get ahead of the opioid crisis in the U.S. with preventative measures. Nonetheless, the need for developing a non-opioid-based treatment approach is high, and there remains optimism for developing a novel therapy to treat pain.

Among pain types, neuropathic pain is anticipated to exhibit remunerative growth in the forthcoming years; this is more likely due to the robust product pipeline with major products in Phase II and Phase III development.

                         Non-opioid Analgesics Market Segmentation             

Segments

Details

By Drug Class

NSAIDs, Acetaminophen, Local Anesthetics

By Pain Type

Post-operative Pain, Cancer Pain, Neuropathic Pain, Others

By Route Of Administration

Oral, Topical, Injectable

By Distribution Channel

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

 

Owing to the uncertain opioid regulatory situation, pharma giants are shifting their focus on non-opioid analgesics, companies such as The WIRB-Copernicus Group’s (WCG) acquired Analgesic Solutions, LLC. Major companies operating in the space include AbbVie Inc.; Pfizer, Inc, Lilly; Teva Pharmaceutical Industries Ltd., Viatris Inc., Centrexion Therapeutics, Cara Therapeutics, Medropharm GmbH.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.